Sanofi Announces Key Leadership Change
Sanofi has announced a significant change at the top: as of March 1st, Manuela Buxo will take the reins of its key division, specialty medicines. This French pharmaceutical giant is thus undergoing a rapid reshuffle at the top, signaling a new dynamic in its leadership.
A Well-Targeted Transfer of Power
Based in Cambridge, Massachusetts, Manuela Buxo is succeeding Brian Foard, who is leaving on February 28th to pursue a new professional adventure outside of Sanofi. Having previously led the group's immunology division, she is joining the executive committee to drive the global strategy of this strategic branch - neuro-inflammation, rare diseases, oncology, and, of course, immunology.
At the heart of this division is Dupixent, the blockbuster that drove 36% of Sanofi's revenue last year. However, the shadow of generics is already looming: its patent expires in 2031, a major challenge that requires bold choices to be made today.
Amidst the Whirlwind of Transitions at Sanofi
This news comes just a week after the surprise dismissal of Paul Hudson, the CEO, who will be replaced in April by Belén Garijo, the head of Merck KGaA. These successive shocks show that Sanofi is accelerating its transformation, in full preparation for a post-Dupixent future.
The Career of an Immunology Expert
Manuela Buxo is no novice: for over two years, she has been orchestrating the global expansion of Dupixent, a pillar of the group's growth. With this new, expanded role, she will have the mission of strengthening the fortress of specialty care, as competition intensifies on all fronts.
